ArticleHaematologica2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
Abstract readLetter
In one paragraph
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.Blood advances · 2020Pooled it
- The Shape-Shifting Myeloma: Adaptive Plasticity as a Hallmark of Relapse and Refractoriness.Cancers · 2026Review
- Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging.Blood advances · 2025Article
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.Blood cancer journal · 2023Article
- Plasma cell neoplasms and related entities-evolution in diagnosis and classification.Virchows Archiv : an international journal of pathology · 2023Review
- Article
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.Blood advances · 2022Article
- Article
- Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.International journal of cancer · 2021Review
- Minimal residual disease in multiple myeloma: why, when, where.Hematology. American Society of Hematology. Education Program · 2021Article
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.Haematologica · 2021Article
- Review
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.Cancers · 2021Article
- Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.Leukemia · 2021Article
- Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.Frontiers in oncology · 2021Review
- Future of CAR T cells in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2020Review
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.Leukemia · 2019Article
- The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.International journal of molecular sciences · 2019Review
- Is molecular remission the goal of multiple myeloma therapy?Hematology. American Society of Hematology. Education Program · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Carolina SchinkeMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA cdschinke@uams.edu gjmorgan@uams.edu.
Antje HoeringCancer Resarch and Biostatistics, Seattle, WA, USA.
Hongwei WangCancer Resarch and Biostatistics, Seattle, WA, USA.
Victoria CarltonAdaptive Biotechnologies, San Francisco, CA, USA.
Sharmilan ThanandrarajanMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shayu DeshpandeMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Purvi PatelMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Gabor MolnarMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Sandra SusanibarMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Meera MohanMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Pankaj MathurMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Muthukumar RadhakrishnanMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shadiqul HoqueMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jorge Jo KamimotoMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Monica GrazziuttiMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Frits van RheeMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Maurizio ZangariMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Giovanni Insuasti-BeltranDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Daisy AlapatDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ginell PostDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shmuel YaccobyMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Joshua EpsteinMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Leo RascheMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Sarah JohnsonMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Martin MoorheadAdaptive Biotechnologies, San Francisco, CA, USA.
Tom WillisAdaptive Biotechnologies, San Francisco, CA, USA.
Bart BarlogieMt. Sinai School of Medicine, New York, NY, USA.
Brian WalkerMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Niels WeinholdMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Faith E DaviesMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Gareth J MorganMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA cdschinke@uams.edu gjmorgan@uams.edu.
Funding
Tumor Cell-Microenvironment Interactions in the Molecular Pathogenesis of MultiplP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI BELLAMY, WILLIAM T · 1993 to 2013
$49.7MNCI NIH HHS P01 CA055819
Abstract
PubMed holds no abstract for this paper.
Indexed as
HumansMultiple MyelomaNeoplasm, ResidualPrognosisRisk AssessmentTime Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.